Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Tsukamoto T, Shuto T, Takemura S, Yamamoto T, Ikebe T, Wakasa K, Shiomi S, Kinoshita H
Second Department of Surgery, Osaka City University Medical School, Abeno-ku, Osaka 545-8585, Japan.
Jpn J Cancer Res. 2001 Jan;92(1):59-66. doi: 10.1111/j.1349-7006.2001.tb01048.x.
Interferon (IFN) therapy decreases the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV). One hundred and fifty-nine consecutive patients who underwent liver resection for HCV-related HCC were studied. In 17 (group 1) of the 159 patients, HCC was detected during or after IFN therapy. The incidences of recurrence after surgery in the group 1 patients and the other 142 patients (group 2) were compared. Eight patients had a complete response to IFN, 4 had a partial response, and 5 had no response. The proportion of patients without HCV viremia was significantly higher in the group 1 patients (P < 0.0001). The tumor-free survival rate was significantly higher in the group 1 patients (P = 0.0010). By multivariate analysis of various risk factors for recurrence, no previous IFN was a significant independent risk factor for recurrence (risk ratio = 6.336; 95%CI, 1.512 - 26.50). The patients with HCC who underwent IFN therapy previously are good candidates for liver resection because recurrence after the operation was rarely observed.
干扰素(IFN)治疗可降低丙型肝炎病毒(HCV)感染患者肝细胞癌(HCC)的发病率。对159例因HCV相关HCC接受肝切除术的连续患者进行了研究。在这159例患者中的17例(第1组)中,HCC是在IFN治疗期间或之后检测到的。比较了第1组患者和其他142例患者(第2组)术后复发的发生率。8例患者对IFN完全缓解,4例部分缓解,5例无反应。第1组患者中无HCV病毒血症的患者比例显著更高(P < 0.0001)。第1组患者的无瘤生存率显著更高(P = 0.0010)。通过对各种复发危险因素进行多因素分析,既往未使用过IFN是复发的显著独立危险因素(风险比 = 6.336;95%CI,1.512 - 26.50)。既往接受过IFN治疗的HCC患者是肝切除术的良好候选者,因为术后很少观察到复发。